NEW YORK (GenomeWeb News) – The Georgia Institute of Technology will partner with Saint Joseph's Hospital in Atlanta to study the genetics and cell biology involved in pancreatic cancer.
Georgia Tech said this week that the partnership involves studying tissue and serum samples with microarray technologies in order to find genetic and cellular differences between normal and tumor cells.
The group will use Affymetrix's microarray technology to conduct gene expression studies and it will study expression by transcriptome sequencing using Roche 454 Life Sciences' sequencing technology.
Findings from these studies will be used to develop tests for early diagnosis and for identifying targeted therapies for pancreatic cancer, Georgia Tech said.
The university expects to find support for the program through donations from private donors and foundations on top of grant funding from the State of Georgia, according to John McDonald, who is chair of the university's School of Biology.
George Daneker, who is medical director of oncology research at Saint Joseph's and who is co-principal investigator on the study, said the program is "a very unique partnership that facilitates rapid discovery and satisfies both our missions to bring the best treatments to patients in the in the quickest, safest way."
Georgia Tech and Saint Joseph's plan to expand the collaboration to research lung cancers sometime this month, and will expand it to include prostate and colorectal cancers in the following months, the university said.